Business Description
Milestone Scientific Inc
NAICS : 339114
SIC : 3842
ISIN : US59935P2092
Description
Milestone Scientific Inc is engaged in pioneering proprietary, technological systems, and solutions for the medical and dental markets. It develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetic. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. In addition, the company provides The Wand, a handpiece that allows dentists to provide painless injections for virtually various dental procedures, including routine cleanings and fillings, as well as implants, root canals, and crowns. The Company conducts its business through two reportable segments: Dental and Medical. Geographically all the operations of the firm function through the region of the U.S.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.04 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -7.87 | |||||
| Beneish M-Score | -3.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.2 | |||||
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 5.9 | |||||
| 3-Year FCF Growth Rate | 13 | |||||
| 3-Year Book Growth Rate | -25.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.32 | |||||
| 9-Day RSI | 40.55 | |||||
| 14-Day RSI | 40.45 | |||||
| 6-1 Month Momentum % | -27.35 | |||||
| 12-1 Month Momentum % | -17.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.51 | |||||
| Quick Ratio | 2.65 | |||||
| Cash Ratio | 1.94 | |||||
| Days Inventory | 267.96 | |||||
| Days Sales Outstanding | 24.51 | |||||
| Days Payable | 106.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.7 | |||||
| Shareholder Yield % | 0.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.11 | |||||
| Operating Margin % | -72.32 | |||||
| Net Margin % | -70.5 | |||||
| FCF Margin % | -54.21 | |||||
| ROE % | -80.73 | |||||
| ROA % | -58.64 | |||||
| ROIC % | -283.87 | |||||
| ROC (Joel Greenblatt) % | -312.14 | |||||
| ROCE % | -81.39 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.51 | |||||
| PB Ratio | 5.53 | |||||
| Price-to-Tangible-Book | 6.09 | |||||
| EV-to-EBIT | -5.13 | |||||
| EV-to-EBITDA | -5.24 | |||||
| EV-to-Revenue | 3.71 | |||||
| EV-to-FCF | -7.01 | |||||
| Price-to-Median-PS-Value | 0.9 | |||||
| Price-to-Net-Current-Asset-Value | 6.2 | |||||
| Price-to-Net-Cash | 20.66 | |||||
| Earnings Yield (Greenblatt) % | -19.49 | |||||
| FCF Yield % | -11.43 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers